Blood conservation in liver transplantation: The role of aprotinin

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 18, Issue 4 SUPPL., 2004, Pages S31-S37

  Porte, Robert J ^a   Hendriks, Herman G D ^a   Slooff, Maarten J H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; APROTININ; SERINE PROTEINASE INHIBITOR;

ALLERGIC REACTION; ANTIINFLAMMATORY ACTIVITY; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; DRUG SAFETY; FIBRINOLYSIS; HUMAN; KIDNEY FAILURE; LIVER TRANSPLANTATION; LUNG EMBOLISM; NEPHROTOXICITY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM;

EID: 4444337346     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2004.05.004     Document Type: Article

References (42)

1. Adam R., McMaster P., O'Grady J.G., et al. European Liver Transplant: Association: Evolution of liver transplantation in Europe: Report of the European Liver Transplant Registry. Liver Transplant. 9:2003;1231-1243
2. Starzl T.E., Marchioro T.L., Von Kaulla K.N., et al. Homotransplantation of the liver in humans. Surg Gynecol Obstet. 117:1963;659-676
3. Bismuth H., Castaing D., Ericzon B.G., et al. Hepatic transplantation in Europe. First Report of the European Liver Transplant Registry. Lancet. ii:1987;674-676
4. Starzl T.E., Iwatsuki S., Van Thiel D.H., et al. Evolution of liver transplantation. Hepatology. 5:1982;614-636
5. Porte R.J., Knot E.A.R., Bontempo F.A. Hemostasis in liver transplantation. Gastroenterology. 97:1989;488-501
6. Porte R.J. Coagulation and fibrinolysis in orthotopic liver transplantation Current views and insights. Semin Thromb Hemost. 19:1993;191-196
7. Porte R.J., Leebeek F.W.G. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drug. 62:2002;2193-2211
8. Ramos E., Dalmau A., Sabate A., et al. Intraoperative red blood cell transfusion in liver transplantation Influence on patient outcome, prediction of requirements, and measures to reduce them. Liver Transplant. 9:2003;1320-1327
9. Mor E., Jennings L., Gonwa T.A., et al. The impact of operative bleeding on outcome in transplantation of the liver. Surg Gynecol Obstet. 176:1993;219-227
10. Bechstein W.O., Neuhaus P. A surgeon's perspective on the management of coagulation disorders before liver transplantation. Liver Transplant Surg. 3:1997;653-655
11. Sieders E., Peeters P.M.J.G., TenVergert E.M., et al. Prognostic factors for long-term actual patient survival after orthotopic liver transplantation in children. Transplantation. 70:2000;1448-1453
12. Hendriks H.G.D., van der Meer J., Klompmaker I.J., et al. Blood loss in orthotopic liver transplantation A retrospective analysis of transfusion requirements and the effects of autotransfusion of cell saver blood in 164 consecutive patients. Blood Coag Fibrinol. 11:2000;S87-S93
13. Cacciarelli T.V., Keeffe E.B., Moore D.H., et al. Effect of intraoperative blood transfusion on patient outcome in hepatic transplantation. Arch Surg. 134:1999;25-29
14. Kang Y.G., Martin D.J., Marquez J., et al. Intraoperative changes in blood coagulation and thromboelastographic monitoring in liver transplantation. Anesth Analg. 64:1985;888-896
15. Porte R.J., Bontempo F.A., Knot E.A.R., et al. Systemic effects of tissue-plasminogen-activator-associated fibrinolysis and the relation with thrombin generation in orthotopic liver transplantation. Transplantation. 47:1989;978-984
16. Kraut E., Frey E.K., Werle E. Über die Inaktivierung des Kallikreins. Hoppe Seyler's Zeitschrift für Physiologische Chemie 1930. 192:1930;1-21
17. Fritz H., Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung. 33:1983;479-494
18. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs. 29:1985;236-261
19. Royston D. High-dose aprotinin therapy A review of the first five years' experience. J Cardiothorac Vasc Anesth. 6:1992;76-100
20. Fischer J.H., Knupfer P. High-dosage aprotinin (Trasylol) therapy - Is it safe for the kidney? Langenbecks Arch Chir. 360:1983;241-249
21. Rustom R., Grime J.S., Maltby P., et al. Observations on the early renal uptake and later tubular metabolism of radiolabelled aprotinin (Trasylol) in man Theoretical and practical considerations. Clin Sci (Colch). 84:1993;231-235
22. Frey E.K. On the treatment of pancreatitis. Therapiewoche. 4:1953;323
23. Bidstrup B.P., Royston D., Sapsford R.N., et al. Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin (Trasylol). J Thorac Cardiovasc Surg. 97:1989;364-372
24. Levi M., Cromheecke M.E., de Jonge E., et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery A meta-analysis of clinically relevant endpoints. Lancet. 354:1999;1940-1947
25. Neuhaus P., Bechstein W.O., Lefebre B., et al. Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation. Lancet. ii:1989;924-925
26. Hunt B.J., Cottam S., Segal H., et al. Inhibition by aprotinin of tPA-mediated fibrinolysis during orthotopic liver transplantation. Lancet. 336:1990;381. (letter)
27. Mallett S.V., Cox D., Burroughs A.K., et al. The intraoperative use of Trasylol (aprotinin) in liver transplantation. Transplant Int. 4:1991;227-230
28. Grosse H., Lobbes W., Frambach M., et al. The use of high-dose aprotinin in liver transplantation The influence on fibrinolysis and blood loss. Thromb Res. 63:1991;287-297
29. Garcia-Huete L., Domenech P., Sabate A., et al. The prophylactic effect of aprotinin on intraoperative bleeding in liver transplantation A randomized clinical study. Hepatology. 26:1997;1143-1148
30. Porte R.J., Molenaar I.Q., Begliomini B., et al. Aprotinin for reducing blood loss and transfusion requirements in orthotopic liver transplantation A multicentre, randomised, double-blind study. Lancet. 355:2000;1303-1309
31. Findlay J.Y., Rettke S.R., Ereth M.H., et al. Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation A prospective, randomized, double-blind study. Liver Transplant. 7:2001;802-807
32. Baubillier E., Cherqui D., Dominique C., et al. A fatal thrombotic complication during liver transplantation after aprotinin administration. Transplantation. 57:1994;1664-1666
33. Fitzsimons M.G., Peterfreund R.A., Raines D.E. Aprotinin administration and pulmonary thromboembolism during orthotopic liver transplantation Report of two cases. Anesth Analg. 92:2001;1418-1421
34. Molenaar I.Q., Porte R.J. Aprotinin and thromboembolism in liver transplantation Is there really a causal effect? Anesth Analg. 94:2002;1367-1368
35. Molenaar I.Q., Legnani C., Groenland T.H.N., et al. Aprotinin in orthotopic liver transplantation Evidence for a prohemostatic, but not a prothrombotic effect. Liver Transplant. 7:2001;896-903
36. Molenaar I.Q., Begliomini B., Grazi G.L., et al. The effect of aprotinin on renal function in orthotopic liver transplantation. Transplantation. 71:2001;247-252
37. Milroy S.J., Cottam S., Tan K.C., et al. Improved haemodynamic stability with administration of aprotinin during orthotopic liver transplantation. Br J Anaesth. 75:1995;747-751
38. Scholz T., Backman L., Mathisen O., et al. Activation of the plasma contact system and hemodynamic changes after graft revascularization in liver transplantation. Transplantation. 60:1995;36-40
39. Molenaar I.Q., Begliomini B., Martinelli G., et al. Reduced need for vasopressors in patients receiving aprotinin during orthotopic liver transplantation. Anesthesiology. 95:2001;433-439
40. Findlay J.Y., Kufner R.P. Aprotinin reduces vasoactive medication use during adult liver transplantation. J Clin Anesth. 15:2003;19-23
41. Mojcick C.F., Levy J.H. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg. 71:2001;745-754
42. Hamilton G., Prettenhofer M., Zommer A., et al. Intraoperative course and prognostic significance of endotoxin, tumor necrosis factor alpha and interleukin-6 in liver transplant recipients. Immunobiol. 182:1991;425-439